You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Molecular/Genetic Therapies in Ovarian Cancer: Future Opportunities and Challenges

ZIEBARTH, ANGELA J. MD; LANDEN, CHARLES N. Jr MD; ALVAREZ, RONALD D. MD

Clinical Obstetrics & Gynecology:
doi: 10.1097/GRF.0b013e31824b1699
Ovarian Cancer
Abstract

Ovarian cancer is the most lethal gynecologic cancer. Traditional therapies have included surgical management and cytotoxic chemotherapy; however, treatment paradigms continue to shift from empiric cytotoxic chemotherapy to more individualized treatment. Recent research efforts have focused on determining and targeting the molecular biological mechanisms of ovarian cancer in an attempt to develop novel therapeutic modalities with the ultimate goal of improving outcome while limiting toxicity. This chapter reviews progress in the development of novel therapies directed at major pathways implicated in ovarian tumorigenesis including angiogenesis, PARP inhibition, signal transduction, antifolate therapies, death receptor-mediated therapies, histone deacetylase inhibition, immunotherapeutics, and oncolytics.

Author Information

The Division of Gynecologic Oncology, The University of Alabama at Birmingham, Birmingham, Albama

R.D.A. does have associations he would like to disclose as follows: Ad board for Genentech and Esai/Morphotec and research support from Morphotec, Pfizer, Genentech, Merrimack, and Tracon. The other authors declare that they have nothing to disclose.

Correspondence: Ronald D. Alvarez, MD, Division of Gynecologic Oncology, University of Alabama at Birmingham, 176F Rm 10250, Birmingham, AL 35249. E-mail: rdalvarez@uab.edu

© 2012 Lippincott Williams & Wilkins, Inc.